English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

To the Editors: as a comment to the editorial of Oderda et al: In an interesting editorial in this issue of the journal, Oderda et al (1) review which tests may be used to diagnose Helicobacter pylori (H. pylori) in children. Some are invasive (i.e. upper gastro-intestinal endoscopy and multiple gastric biopsies), and some are non invasive (i.e. serology, C-urea breath test and stool antigen determination). All exhibit various advantages or disadvantages, and for that purpose, their respective place in the diagnosis decision tree differ. In symptomatic children, as clearly stated by the position papers of both the European Task Force for H. pylori infection in children (2) and NASPGAN (3), upper gastrointestinal endoscopy with gastric biopsies remains the gold standard method for the diagnosis of H. pylori gastritis in children. Non-invasive tests are non longer recommended to screen children with abdominal pain. Some new approaches may currently be suggested. Recently, a new EIA blood panel test (Biohit , Helsinki, Finland), has been developed, associating group-I pepsinogens (PGI), group-II pepsinogens (PGII), gastrin-17 (G-17), and H. pylori antibodies, and proposed as a non endoscopic tool for diagnosis and screening of chronic and atrophic gastritis in adults (4–6). In children, such an alternative procedure has not yet been investigated. PGI are synthesized solely in the oxyntic glands and mucus neck cells of the gastric corpus, whereas, PGII are uniformly formed in the glands of the entire stomach and to some extent in the Brunner glands in the first part of the duodenum. In case of atrophic corpus gastritis, the level of serum PGI decreases, whereas the level of PGII remains stable or decreases slightly. Thus, the level of the serum PGI/PGII ratio decreases proportionally to the severity of corpus atrophic gastritis (4). Gastrin is synthesized in G-cells, which are found in the antrum, the most important one being G-17. In case of atrophic antral gastritis and loss of antral G cells, serum G-17 remains low although the stomach is achlorhydric or hypochlorhydric (4). In this new EIA blood panel test, panels include assays of postprandial (after stimulation with protein-rich drink) serum gastrin (G-17prand) which seems to be much more accurate with a higher sensitivity and specificity as compared to basal fasting serum gastrin (G-17fast) (5,6). Using an algorithm, this blood test panel is able to establish with high sensitivity and specificity whether the patient has gastritis, whether this gastritis is atrophic or not and in which part of the stomach the atrophic changes are located. The algorithm (decision tree) is used for classification of patients into different categories of atrophic gastritis by the H. pylori antibody titers, upon the cutoff levels of PGI and G-17prand. The absence of evidence of H. pylori infection is considered to indicate an autoimmune origin of gastritis (4). Finally, H. pylori gastritis, without gastric atrophy, tends to raise the serum levels of G-17 and PGI. A low intragastric acidity increases the serum levels of G-17 and vice versa. Permanent, long-lasting hypoor achlorhydria results in extremely high levels of circulating G-17, possibly due to antral G-cells hyperplasia (6). The aim of our study was a preliminary assessment of this new non endoscopic blood panel test in the course of H. pylori related gastritis in pediatrics. An observational retrospective study was performed in 100 children, mean age 10 years (1–18), 52 females and 48 males, who underwent diagnostic upper-gastrointestinal endoscopy for various dyspeptic symptoms, recurrent abdominal pain and vomiting. Gastric biopsies were taken in antrum and corpus, at least 2 from each site, for histologic and bacterial culture assessment. Histological analysis, H. pylori, chronic inflammation, activity, atrophy, and intestinal metaplasia were noted and graded according to the updated Sydney System. H. pylori infection was considered for gastric biopsies with positive histology and/or culture. Within the same day, fasting serum samples were also analysed using the EIA blood panel tests for H. pylori antibodies (cut-off levels .38 EIU), PGI, PGII and G-17fast (Biohit , Helsinki, Finland). Non parametric MannWhitney U test was used in the calculation of the significance between groups, the StatView Software (Abacus , CA, USA) values were considered significant when P , 0.05. The sensitivity, specificity, positive and negative predictive values and test accuracy of the H. pylori antibodies were calculated and compared to the results of gastric biopsies. Finally, written parental consent was obtained from all. There were 64 H. pylori positives (Hp+ve) and 36 H. pylori negatives (Hp2ve). Among them 61 Hp+ve (95.3%) and 3 Hp2ve (8.3%) had evidence of chronic superficial gastritis, mild (25), moderate (21) and severe (13). None exhibited gastric atrophy or intestinal metaplasia. Serum PGI and PGII levels showed a significant increase and the PGI/PGII ratio significantly decreased in Hp+ve children as compared to Hp2ve ones, P , 0.0002. No significant variation of G-17fast serum level occurred between Hp+ve and Hp2ve children, Table 1. Compared to gastric biopsies, H. pylori antibodies showed 3 false positive and 23 false negative results. Their

P0521 SERUM LEVELS OF PEPSINOGEN I, PEPSINOGEN II AND GASTRIN-17 IN THE COURSE OF HELICOBACTER PYLORI GASTRITIS IN PAEDIATRICS